HIV replication and pathogenesis

Current Opinion in Infectious Diseases

Volumn 9, Issue 1, 1996, Pages 7-13

  Grant, Robert M ^a   Feinberg, Mark B ^b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; EVOLUTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; T LYMPHOCYTE; VIRUS MUTANT; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0029915217     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199602000-00003     Document Type: Review

References (64)

1. Haseltine W: Silent HIV infections. N Engl J Med 1989, 320:1487-1488.
2. Ho DD, Moudgil T, Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of Infected persons. N Engl J Med 1989, 321:1621-1625.
3. Baltimore D, Feinberg MB: HIV revealed: toward a natural history of the infection [editorial; comment]. N Engl J Med 1989, 321:1673-1675.
4. Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L: Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989, 321:1626-1631.
5. Piatak MJ, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122. Observations of patients treated with Nevirapine (an NNRTI) and protease inhibitors indicate that plasma virions and virus producing cells are cleared rapidly, with half lives of less than 2 days. Similar findings are found with both classes of drugs, making artifactual effects of drugs on virion clearance unlikely.
7. + count surges which may help to distinguish between thymic and peripheral lymphocyte production.
8. Cao Y, Ho DD, Todd J, Kokka R, Urclea M, Lifson JD, Piatak M Jr, Chen S: Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retrovir 1995, 11:353-361.
9. Piatak M Jr, Luk KC, Williams B, Lifson JD: Quantitative competitive polymerase chain reaction for accurate quantltation of HIV DNA and RNA species. Biotechniques 1993, 14:70-81.
10. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, et al.: A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med 1993, 329:1065-1072.
11. Mellors J, Kingsley L, Rinaldo C, Todd J, Hoo B, Kokka R, Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122. A prospective study of 62 men found that high level plasma viremia (100 000 Eq/ml) after HIV seroconversion was associated with higher risk of clinical progression to AIDS in the following 4 years.
12. Hogervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F, Goudsmit J: Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
13. Jurriaans S, Van Gemen B, Weverling G, Van Strup D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J: The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994, 204:223-233. A significant decrease in plasma viral load after seroconversion was associated with slower disease progression among 20 men in a prospective cohort study.
14. Ho D: Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
15. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation of period of AIDS. Nature 1993, 362:359-362.
16. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
17. Nowak M, Bonhoeffer S, Loveday C, Balfe P, Semple M, Kaye S, Tenant-Flowers M, Tedder R: Results Confirmed. Nature 1995, 375:193.
18. Koenig S, Conley A, Brewah Y, Jones G, Leath S, Boots L, Davey V, Pantaleo G, Demarest J, Carter C, et al.: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection of HIV variants and subsequent disease progression. Nature Medicine 1995, 1:330.
19. Couillin I, Culmann PB, Gomard E, Choppin J, Levy JP, Guillet JG, Saragosti S: Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 nef protein. J Exp Med 1994, 180:1129-1134.
20. Nowak M, May R, Phillips R, Rowland-Jones S, Lalloo D, McAdam S, Klenerman P, Koppe B, Sigmund K, Bangham C, McMichael A: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995, 375:606-611. Epitope sequences over time in two HIV-1 infected patients are used to demonstrate a mathematical model of shifting immunodominance. The model predicts that viral mutations in the immunodominant epitope would allow viral escape from immune responses, increases in viral load, increases in viral diversification, and finally disease progression.
21. Delwart E, Sheppard H, Walker B, Goudsmit J, Mullins J: Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994, 68:6672-6683. Heteroduplex mobility assays are used to track viral envelope diversification in vivo. Viral envelope diversity is found to be homogeneous shortly after infection, followed by a period of envelope diversity, followed by increasing homogeneity.
22. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May RM: Antigenic diversity thresholds and the development of AIDS. Science 1991, 254:963-969.
23. Cheng-Mayer C, Seto D, Tateno M, Levy JA: Biologic features of HIV-1 that correlate with virulence in the host Science 1988, 240:80.
24. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
25. Korber B, Kunstman K, Patterson B, Furtado M, McEvilly M, Levy R, Wolinsky S: Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virology 1994, 68:7467-7481.
26. Layne S, Merges M, Dembo M, Spouge J, Conley S, Moore J, Raina J, Renz H, Gelderblom H, Nara P: Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992, 189:695-714.
27. Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux J: Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J AIDS 1992, 5:359-364.
28. Najera I, Holguin A, Quinones MM, Munoz FM, Najera R, Lopez GC, Domingo E: Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
29. Frost S, McLean A: Quasispecies dynamics and the emergence of drug resistance during ziduvudine therapy of HIV infection. AIDS 1994, 8:323-332.
30. Kinloch-de-Loes S, Hirshcel B, Hoen B, Cooper D, Tindall B, Carr A, Saurat J, Clumeck N, Lazzarin A, Mathiesen L, et al.: A controlled trial of ziduvudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
31. Concorde Coordinating Committee: Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
32. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HJ, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT: The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994, 272:437-442.
33. Emini E, Graham D, Gotlib L, Condra J, Byrnes V, Schleif W: HIV and multidrug resistance [Letter]. Nature 1993, 364:679.
34. Chow Y-K, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila R: Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993, 361:650-654.
35. Chow Y, Hirsch M, Kaplan J, D'Aguila R: HIV-1 error revealed [Letter]. Nature 1993, 364:679.
36. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner S, Mulder J, Loveday C, Christopherson C: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419. Plasma viral load and CD4 counts were followed after initiating treatment with 3TC. The baseline level of viremia on treatment is less than pretreatment levels despite the emergence of drug resistant virus. This suggests that the resistant genotype may have a partially sensitive phenotype or that the resistant virus has a diminished replicative capacity.
37. Tisdale M, Kemp S, Parry N, Larder B: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
38. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699. Mutant viruses resistant to AZT became phenotypically insensitive in vitro by an additional mutation that induced resistance to 3TC (M184V). AZT-3TC co-resistance was not observed during extensive in-vitro selection, or in patients treated with both drugs. Viral load during treatment was lower with combination therapy than with AZT alone.
39. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
40. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489. This extensive review describes several of the principles of viral population biology that underly recent studies of viral dynamics in vivo. The prevalence of drug resistant mutants is predicted to depend on the selective disadvantage of the mutant relative to the wild-type virus after the virus population achieves a steady state.
41. Shaw G, Wei X, Ghosh S, Johnson V, Deutsch P, Emini E, Lifson J, Nowak M, Hahn B, Saag M: Viral dynamics in HIV-1 infection [Keystone abstract #04-006]. J Cell Biochem 1995, 21B:181.
42. McLean A, Michie C: In vivo estimates of division and death rates of human I lymphocytes. PNAS 1995, 92:3707-3711. The authors use mathematical models and observations of chromosomal damage after radiation therapy to derive estimates of proliferation rates of naive and memory class human T lymphocytes. They deduce that naive lymphocytes divide once every 3.5 years and memory lymphocytes divide every 22 weeks. Decay of lymphocytes with stable chromosome damage is very slow.
43. Michie C: Toxic shock. Nature 1995, 375:197-198.
44. + cell turnover. Nature 1995, 375:193-194.
45. + cell turnover. Nature 1995, 375:194.
46. + cell turnover. Nature 1995, 375:194-195.
47. Margolick J, Munoz A, Donnenberg A, Park L, Galai N, Giorgi J, O'Gorman M, Ferbas J: Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nature Medicine 1995, 1:674-680. Analysis of a large cohort indicates that total T cells remain relatively stable through most of the course of HIV infection, which is consistent with regulation of total T cell number. A steady decline in total T cell count begins approximately 18 months prior to the onset of AIDS, suggesting a failure of 'blind T cell homeostasis'.
48. Adleman L, Wofsy D: T-cell homeostasis: implications in HIV infection. J AIDS 1993, 6:144-152.
49. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, Kaneshima H: HIV induces thymus depletion in vivo. Nature 1993, 363:728-732.
50. + T cells in adults is caused by expansion of memory cells. This decreases the host's ability to respond to novel antigens and will affect circulating cytokine profiles.
51. + cells may contribute to the defects in cell mediated immunity associated with HIV disease progression.
52. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149. Recovery of CD4 cells after chemotherapy is found to be faster in younger patients who have larger thymic mass on computed tomography. A role for the thymus in T cell proliferation of adults is suggested.
53. Chaisson R, Keruly J, Moore R: Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
54. Michie C, Scott A, Cheesbrough J, Beverley P, Pasvol G: Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immun 1994, 98:140-144.
55. Saksela K, Stevens C, Rubinstein P, Baltimore D: Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the number of CD4 lymphocytes. Proc Natl Acad Sci USA 1994, 91:1104-1108.
56. Zhu T, Mo H, Wang N, Nam D, Cao Y, Koup R, Ho D: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179-1181.
57. McCune J: Viral latency in HIV disease. Cell 1995, 82:183-188.
58. Wain-Hobson S: Virological mayhem. Nature 1995, 373:102.
59. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection [see comments]. N Engl J Med 1995, 332:228-232.
60. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
61. Coffin J: Lines drawn in epitope wars. Nature 1995, 375:534-535.
62. Staprans S, Hamilton B, Elbeik T, Barbosa P, Grant R, Feinberg M: Activation of virus replication following vaccination of HIV-1 infected individuals. J Exp Med 1995, in press.
63. McLean A, Nowak M: Models of interactions between HIV and other pathogens. J Theor Biol 1992, 155:69-102.
64. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995, 332:567-575.